TargetMol

BRD5648

Product Code:
 
TAR-T10608
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T10608-1mg1mg£156.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10608-5mg5mg£266.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10608-1mL1 mL * 10 mM (in DMSO)£278.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10608-10mg10mg£358.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10608-25mg25mg£551.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10608-50mg50mg£756.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10608-100mg100mg£1,018.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
BRD5648 is an inactive (R)-enantiomer of BRD0705. BRD0705 is a GSK3α inhibitor (IC50: 66 nM; Kd: 4.8 μM) and can be used in acute myeloid leukemia (AML) studies.
CAS:
2056261-42-6
Formula:
C20H23N3O
Molecular Weight:
321.424
Pathway:
Stem Cells; PI3K/Akt/mTOR signaling
Purity:
0.98
SMILES:
CC[C@]1(C2=CNNC2=NC2=C1C(=O)CC(C)(C)C2)c1ccccc1
Target:
GSK-3

References

1. Wagner FF, et al. Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Sci Transl Med. 2018 Mar 7;10(431). 2. Scolnick Edward, et al. Preparation of substituted pyrazoloquinolinones as paralog-?selective inhibitors of GSK3 kinases. US20160375006A1